{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T01:09:52Z","timestamp":1711760992678},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"DOI":"10.7759\/cureus.57149","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T04:21:05Z","timestamp":1711686065000},"source":"Crossref","is-referenced-by-count":0,"title":["Utility of COVID-19 Seropositive Plasma as Convalescent Plasma: An Immune and Neutralization Antibody Seroprevalence Analysis in Blood Donors for Future Potential Pandemic Readiness"],"prefix":"10.7759","author":[{"given":"Ashish","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gita","family":"Negi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daljit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivekanandhan","family":"S","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vartika","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal A","year":"2020","unstructured":"Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020, 371:m3939. 10.1136\/bmj.m3939","journal-title":"BMJ"},{"key":"ref2","unstructured":"Clinical management protocol. COVID-19. (2020). Accessed: March 12, 2024: http:\/\/clinicalestablishments.gov.in\/WriteReadData\/2801.pdf."},{"key":"ref3","unstructured":"A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma to limit COVID-19 associated complications in moderate disease. (2020). Accessed. March 14, 2024: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadPublic_NoticesFiles\/ICMR%20Convalescent%20plasma%20_...."},{"key":"ref4","unstructured":"Toolkit updated 01\/14\/22 COVID-19 convalescent plasma (CCP) under emergency use authorization. (2022). Accessed. December 30, 2022: https:\/\/www.aabb.org\/docs\/default-source\/default-document-library\/regulatory\/toolkit-for-ccp-under-eua.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum Y","year":"2020","unstructured":"Weisblum Y, Schmidt F, Zhang F, et al.. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020, 9:e61312. 10.7554\/eLife.61312","journal-title":"Elife"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/v13040697","article-title":"Characteristics of anti-SARS-CoV-2 antibodies in recovered COVID-19 subject","volume":"13","author":"Huynh A","year":"2021","unstructured":"Huynh A, Arnold DM, Smith JW, et al.. Characteristics of anti-SARS-CoV-2 antibodies in recovered COVID-19 subject. Viruses. 2021, 13:697. 10.3390\/v13040697","journal-title":"Viruses"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X09340584","article-title":"Using the principles of randomized controlled trial design to guide test evaluation","volume":"29","author":"Lord SJ","year":"2009","unstructured":"Lord SJ, Irwig L, Bossuyt PM. Using the principles of randomized controlled trial design to guide test evaluation. Med Decis Making. 2009, 29:E1-12. 10.1177\/0272989X09340584","journal-title":"Med Decis Making"},{"key":"ref8","unstructured":"COVID 19 neutralizing antibody Microlisa. (2021). Accessed. December 28, 2022: https:\/\/jmitra.co.in\/wp-content\/uploads\/2021\/10\/Instruction-Manual-Covid-19-Neutralizing-Antibodies-Microlisa.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-021-01512-y","article-title":"SARS-CoV-2 seroprevalence among whole blood donors during first wave of COVID-19 pandemic in India","volume":"38","author":"Chunchu SR","year":"2022","unstructured":"Chunchu SR, Ravula U, Gente VK, Bacchu S, Pandu Ranga Rao S, Mooli S. SARS-CoV-2 seroprevalence among whole blood donors during first wave of COVID-19 pandemic in India. Indian J Hematol Blood Transfus. 2022, 38:546-55. 10.1007\/s12288-021-01512-y","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref10","unstructured":"Clinical guidance for management of adult COVID-19 patients. (2021). Accessed. April 22, 2021: https:\/\/www.scribd.com\/document\/507944234\/AIIMS-COVID-Algorithm-Ver-2-0-1."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16580","article-title":"Assessment of serological assays for identifying high titer convalescent plasma","volume":"61","author":"Farnsworth CW","year":"2021","unstructured":"Farnsworth CW, Case JB, Hock K, et al.. Assessment of serological assays for identifying high titer convalescent plasma. Transfusion. 2021, 61:2658-67. 10.1111\/trf.16580","journal-title":"Transfusion"},{"key":"ref12","unstructured":"Over 75% people in these states have covid antibodies. ICMR survey. (2021). Accessed: March 12, 2024: https:\/\/www.livemint.com\/news\/india\/these-states-have-over-75-seropositivity-icmr-s-national-sero-survey-finds-116274...."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.12.353","article-title":"Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020-August 2021: a systematic review and meta-analysis","volume":"116","author":"Jahan N","year":"2022","unstructured":"Jahan N, Brahma A, Kumar MS, Bagepally BS, Ponnaiah M, Bhatnagar T, Murhekar MV. Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020-August 2021: a systematic review and meta-analysis. Int J Infect Dis. 2022, 116:59-67. 10.1016\/j.ijid.2021.12.353","journal-title":"Int J Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103419","article-title":"SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 epidemic","volume":"68","author":"Schoenhals M","year":"2021","unstructured":"Schoenhals M, Rabenindrina N, Rakotondramanga JM, et al.. SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 epidemic. EBioMedicine. 2021, 68:103419. 10.1016\/j.ebiom.2021.103419","journal-title":"EBioMedicine"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13132-020-00696-4","article-title":"Linkages between economic growth and population ageing with a knowledge spillover effect","volume":"12","author":"Maity S","year":"2021","unstructured":"Maity S, Sinha A. Linkages between economic growth and population ageing with a knowledge spillover effect. J Knowl Econ. 2021, 12:1905-24. 10.1007\/s13132-020-00696-4","journal-title":"J Knowl Econ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3201\/eid2804.211961","article-title":"SARS-CoV-2 IgG seroprevalence among blood donors as a monitor of the COVID-19 epidemic, Brazil","volume":"28","author":"Chaves DG","year":"2022","unstructured":"Chaves DG, Takahashi RH, Campelo F, et al.. SARS-CoV-2 IgG seroprevalence among blood donors as a monitor of the COVID-19 epidemic, Brazil. Emerg Infect Dis. 2022, 28:734-42. 10.3201\/eid2804.211961","journal-title":"Emerg Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64206","article-title":"Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys","volume":"10","author":"Larremore DB","year":"2021","unstructured":"Larremore DB, Fosdick BK, Bubar KM, et al.. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. Elife. 2021, 10:e64206. 10.7554\/eLife.64206","journal-title":"Elife"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.12.027","article-title":"Seroprevalence of SARS-CoV-2 antibodies in 2115 blood donors from Romania","volume":"27","author":"Olariu TR","year":"2021","unstructured":"Olariu TR, Lighezan R, Ursoniu S, Craciun AC, Paduraru AA, Lupu MA. Seroprevalence of SARS-CoV-2 antibodies in 2115 blood donors from Romania. Clin Microbiol Infect. 2021, 27:817-9. 10.1016\/j.cmi.2020.12.027","journal-title":"Clin Microbiol Infect"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003877","article-title":"Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: a population-based cross-sectional study","volume":"18","author":"Murhekar MV","year":"2021","unstructured":"Murhekar MV, Bhatnagar T, Thangaraj JW, et al.. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: a population-based cross-sectional study. PLoS Med. 2021, 18:e1003877. 10.1371\/journal.pmed.1003877","journal-title":"PLoS Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.24018\/ejmed.2022.4.1.1132","article-title":"4th National sero survey of India: vaccine generated antibodies enhancement","volume":"4","author":"Shervani Z","year":"2022","unstructured":"Shervani Z, Bhardwaj D, Nikhat R, et al.. 4th National sero survey of India: vaccine generated antibodies enhancement. Eur J Med Health Res. 2022, 4:27-32. 10.24018\/ejmed.2022.4.1.1132","journal-title":"Eur J Med Health Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.07.033","article-title":"Effectiveness of BBV152\/Covaxin and AZD1222\/Covishield vaccines against severe COVID-19 and B.1.617.2\/Delta variant in India, 2021: a multi-centric hospital-based case-control study","volume":"122","author":"Bhatnagar T","year":"2022","unstructured":"Bhatnagar T, Chaudhuri S, Ponnaiah M, et al.. Effectiveness of BBV152\/Covaxin and AZD1222\/Covishield vaccines against severe COVID-19 and B.1.617.2\/Delta variant in India, 2021: a multi-centric hospital-based case-control study. Int J Infect Dis. 2022, 122:693-702. 10.1016\/j.ijid.2022.07.033","journal-title":"Int J Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab483","article-title":"Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1","volume":"74","author":"Yadav PD","year":"2022","unstructured":"Yadav PD, Sapkal GN, Abraham P, et al.. Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1. Clin Infect Dis. 2022, 74:558-9. 10.1093\/cid\/ciab483","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-022-09265-0","article-title":"Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review","volume":"70","author":"Das S","year":"2022","unstructured":"Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunol Res. 2022, 70:289-315. 10.1007\/s12026-022-09265-0","journal-title":"Immunol Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals","volume":"584","author":"Zost SJ","year":"2020","unstructured":"Zost SJ, Gilchuk P, Case JB, et al.. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. Nature. 2020, 584:443-9. 10.1038\/s41586-020-2548-6","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes CO","year":"2020","unstructured":"Barnes CO, Jette CA, Abernathy ME, et al.. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020, 588:682-7. 10.1038\/s41586-020-2852-1","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000515610","article-title":"Donors for SARS-CoV-2 convalescent plasma for a controlled clinical trial: donor characteristics, content and time course of SARS-CoV-2 neutralizing antibodies","volume":"48","author":"K\u00f6rper S","year":"2021","unstructured":"K\u00f6rper S, Jahrsd\u00f6rfer B, Corman VM, et al.. Donors for SARS-CoV-2 convalescent plasma for a controlled clinical trial: donor characteristics, content and time course of SARS-CoV-2 neutralizing antibodies. Transfus Med Hemother. 2021, 48:137-47. 10.1159\/000515610","journal-title":"Transfus Med Hemother"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148832","article-title":"SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities","volume":"131","author":"Casadevall A","year":"2021","unstructured":"Casadevall A, Henderson JP, Joyner MJ, Pirofski LA. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. J Clin Invest. 2021, 131:e148832. 10.1172\/JCI148832","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600.pub2","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"7","author":"Piechotta V","year":"2020","unstructured":"Piechotta V, Chai KL, Valk SJ, et al.. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020, 7:CD013600. 10.1002\/14651858.CD013600.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref29","unstructured":"Sentinels of the soil. A tribute to Frontline and Healthcare workers in India\u2019s fight against COVID-19. (2020). Accessed. March 28, 2024: https:\/\/www.mohfw.gov.in\/pdf\/SentinelsoftheSoilSOILCOLOUR01092021.pdf."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2174\/2772434417666220622140416","article-title":"Convalescent plasma-the experience and journey from blockbuster to incognito: a single centre experience","volume":"18","author":"Negi G","year":"2023","unstructured":"Negi G, Kaur D, Jain A, et al.. Convalescent plasma-the experience and journey from blockbuster to incognito: a single centre experience. Recent Adv Antiinfect Drug Discov. 2023, 18:188-96. 10.2174\/2772434417666220622140416","journal-title":"Recent Adv Antiinfect Drug Discov"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/212134-utility-of-covid-19-seropositive-plasma-as-convalescent-plasma-an-immune-and-neutralization-antibody-seroprevalence-analysis-in-blood-donors-for-future-potential-pandemic-readiness","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T04:21:12Z","timestamp":1711686072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/212134-utility-of-covid-19-seropositive-plasma-as-convalescent-plasma-an-immune-and-neutralization-antibody-seroprevalence-analysis-in-blood-donors-for-future-potential-pandemic-readiness"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.57149","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,28]]}}}